Table 2.
Efficacy of yokukansan in patients with traumatic brain injury (n = 7)
| Mean ± SD | P‐value | F‐value | ||
|---|---|---|---|---|
| GCS | 0 | 11.1 ± 2.5 | 0.001 | 36.412 |
| 1 | 14 ± 1.8 | |||
| 2 | 14.6 ± 1.1 | |||
| NPI | 0 | 40.8 ± 17.2 | 0.016 | 9.772 |
| 1 | 17.4 ± 20.3 | |||
| 2 | 6.0 ± 5.8 | |||
| MMSE | 0 | 1.4 ± 3.1 | 0.029 | 10.022 |
| 1 | 16.2 ± 11.4 | |||
| 2 | 17.6 ± 11.0 | |||
| BI | 0 | 9.0 ± 20.1 | 0.043 | 6.833 |
| 1 | 47 ± 41.1 | |||
| 2 | 56 ± 38.5 | |||
| VI | 0 | 2.0 ± 2.3 | 0.013 | 14.247 |
| 1 | 5.8 ± 3.1 | |||
| 2 | 8.0 ± 2.9 |
0, At first treatment; 1, 1 week after commencement of treatment; 2, 2 weeks after commencement of treatment; BI, Barthel Index; GCS, Glasgow Coma Scale; MMSE, Mini‐Mental State Examination; NPI, Neuropsychiatric Inventory; SD, standard deviation; VI, Vitality Index.